caa a22 4500 606179674 CHVBK 20210128100802.0 cr unu---uuuuu 210128e20150401xx s 000 0 eng 10.1007/s11136-014-0834-1 doi (NATIONALLICENCE)springer-10.1007/s11136-014-0834-1 Validity of EQ-5D-5L in stroke [Elektronische Daten] [Dominik Golicki, Maciej Niewada, Julia Buczek, Anna Karlińska, Adam Kobayashi, M. Janssen, A. Pickard] Purpose: To assess EQ-5D-5L (5L) validity in patients with acute stroke, in comparison with EQ-5D-3L (3L). Methods: Cross-sectional study of 408 patients during index hospitalization. We compared 5L and 3L in terms of feasibility, frequency of unique health states, ceiling effect and discriminatory power (informativity). We assessed construct validity in terms of known-groups validity and convergent validity of 5L dimensions with other stroke outcome measures. Results: The overall proportion of patients with acute stroke reporting ‘no problems' with 3L—6.1% was further reduced to 5.6% with 5L (relative reduction of 8.2%). The highest improvement in relative discriminatory power, when moving from 3L to 5L, was noticed in pain/discomfort and anxiety/depression dimensions (Shannon Evenness Index 0.91 for both 5L dimensions; relative increase 34.4 and 29.1%, respectively). Known-groups validity tests confirmed prior hypotheses: Health state utilities were lower in following subpopulations—females, patients with high modified Rankin Scale (mRS) score, low Barthel Index (BI) or VAS score, patients with subarachnoid hemorrhage or intracerebral hemorrhage, and when proxy respondent was used. Convergence of EQ-5D-5L dimensions with mRS, BI and EQ VAS was improved or at least the same as for 3L dimensions. Conclusions: Results support the validity of the EQ-5D-5L descriptive system as a generic health outcome measure in patients with acute stroke, demonstrating some psychometric advantages in comparison with EQ-5D-3L. The Author(s), 2014 EQ-5D-5L nationallicence Health-related quality of life nationallicence Patient-reported outcomes nationallicence Psychometrics nationallicence Stroke nationallicence Golicki Dominik Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Banacha 1b St, 02-097, Warsaw, Poland aut Niewada Maciej Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Banacha 1b St, 02-097, Warsaw, Poland aut Buczek Julia 2nd Department of Neurology, Institute of Psychiatry and Neurology, Jana III Sobieskiego 9 St, 02-957, Warsaw, Poland aut Karlińska Anna 2nd Department of Neurology, Institute of Psychiatry and Neurology, Jana III Sobieskiego 9 St, 02-957, Warsaw, Poland aut Kobayashi Adam 2nd Department of Neurology, Institute of Psychiatry and Neurology, Jana III Sobieskiego 9 St, 02-957, Warsaw, Poland aut Janssen M. Department of Medical Psychology and Psychotherapy, Erasmus MC, Erasmus University, PO Box 2040, 3000 CA, Rotterdam, The Netherlands aut Pickard A. Department of Pharmacy Systems, Outcomes, and Policy, College of Pharmacy, University of Illinois at Chicago, 833 South Wood St, MC886, Chicago, IL, USA aut Quality of Life Research Springer International Publishing 24/4(2015-04-01), 845-850 0962-9343 24:4<845 2015 24 11136 https://doi.org/10.1007/s11136-014-0834-1 text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 brief-communication jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s11136-014-0834-1 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Golicki Dominik Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Banacha 1b St, 02-097, Warsaw, Poland aut NATIONALLICENCE 700 1- Niewada Maciej Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Banacha 1b St, 02-097, Warsaw, Poland aut NATIONALLICENCE 700 1- Buczek Julia 2nd Department of Neurology, Institute of Psychiatry and Neurology, Jana III Sobieskiego 9 St, 02-957, Warsaw, Poland aut NATIONALLICENCE 700 1- Karlińska Anna 2nd Department of Neurology, Institute of Psychiatry and Neurology, Jana III Sobieskiego 9 St, 02-957, Warsaw, Poland aut NATIONALLICENCE 700 1- Kobayashi Adam 2nd Department of Neurology, Institute of Psychiatry and Neurology, Jana III Sobieskiego 9 St, 02-957, Warsaw, Poland aut NATIONALLICENCE 700 1- Janssen M. Department of Medical Psychology and Psychotherapy, Erasmus MC, Erasmus University, PO Box 2040, 3000 CA, Rotterdam, The Netherlands aut NATIONALLICENCE 700 1- Pickard A. Department of Pharmacy Systems, Outcomes, and Policy, College of Pharmacy, University of Illinois at Chicago, 833 South Wood St, MC886, Chicago, IL, USA aut NATIONALLICENCE 773 0- Quality of Life Research Springer International Publishing 24/4(2015-04-01), 845-850 0962-9343 24:4<845 2015 24 11136